SOPHIA ANTIPOLIS, France, Aug. 30 -- The European Society of Cardiology issued the following news release:

* * *

No improvements with mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy

* There are currently no approved therapies for nonobstructive hypertrophic cardiomyopathy (HCM).

* The ODYSSEY-HCM trial compared the cardiac myosin inhibitor, mavacamten, with placebo in patients with symptomatic nonobstructive HCM.

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Submit Form Click here for more information about our products